Abnormal Savda Munziq is a well-known complex prescription of TUM for adjust and regulate Abnormal Savda,and widely used in the prevention and treatment of many chronic diseases such as cancer,hypertension,diabetes me...Abnormal Savda Munziq is a well-known complex prescription of TUM for adjust and regulate Abnormal Savda,and widely used in the prevention and treatment of many chronic diseases such as cancer,hypertension,diabetes mellitus,and memory dysfunction,the diseases which are associated with Abnormal Savda and whose symptomatic expression is known as abnormal Savda Syndrome.In this review,we discuss the possible mechanism of Abnormal Savda Munziq for the treatment of Abnormal Savda Syndrome.展开更多
Objective： To investigate whether administrating Abnormal Savda Munziq （ASMq）, a traditional Uighur herbal preparation used for the prevention or treatment of diseases, affects hypertrophic scar （HTS） formation b...Objective： To investigate whether administrating Abnormal Savda Munziq （ASMq）, a traditional Uighur herbal preparation used for the prevention or treatment of diseases, affects hypertrophic scar （HTS） formation by using an established rabbit ear model. Methods： The HTS rabbit model was created by circular full- thickness skin excisions on both ears of rabbits. Twenty rabbits were randomized into four groups, with 5 rabbits and 60 wounds in each group. Group A was the control group, treated with normal saline daily. Groups B, C, and D were the treatment groups at three different doses of ASMq （400, 800, and 1200 mg/kg body weight, respectively, daily, by gastrogavage）. Twenty wounds were randomly chosen from each group on the 40th day after treatment and specimen were examined. Scar elevation index （SEI） was analyzed with histological assessment, and ultrastructure analysis was analyzed with a transmission electron microscopy. Results： Groups B, C, and D demonstrated significant reductions in SEI as compared with the control group at 35.9% （P=0.0212）, 48.2% （P=0.0108）, and 52.7% （P=0.0103）, respectively in a dose-response manner. SEI was lowered in Group D compared with Group B with a significant difference （P=0.015）. However, there were no significant differences between Groups B and C, or between Groups C and D. Histological analysis showed that high- dose ASMq （1200 mg/kg） could enhance the softening of HTS of rabbit ears and increase the compliance as shown in general. Ultrastructure analysis showed that with increased ASMq dose, the fibroblasts, pro-collagen, collagen, endoplasmic reticulum and ribosomes were reduced gradually. Conclusions： Orally administered ASMq significantly reduces the severity of HTS in the rabbit ear model. The findings of this study may have clinical implications on the management of human HTS.展开更多
基金supported by the Prophase Research of National Basic Research Program of China(973 Program,2011CB 512004)Research program of the Top-Level Foreigner Experts of 2012(Culture and Education Category,GDW20126500222)
文摘Abnormal Savda Munziq is a well-known complex prescription of TUM for adjust and regulate Abnormal Savda,and widely used in the prevention and treatment of many chronic diseases such as cancer,hypertension,diabetes mellitus,and memory dysfunction,the diseases which are associated with Abnormal Savda and whose symptomatic expression is known as abnormal Savda Syndrome.In this review,we discuss the possible mechanism of Abnormal Savda Munziq for the treatment of Abnormal Savda Syndrome.
基金Supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region of China(No.2009211A16)the National Natural Science Foundation of China(No.81260291)
文摘Objective： To investigate whether administrating Abnormal Savda Munziq （ASMq）, a traditional Uighur herbal preparation used for the prevention or treatment of diseases, affects hypertrophic scar （HTS） formation by using an established rabbit ear model. Methods： The HTS rabbit model was created by circular full- thickness skin excisions on both ears of rabbits. Twenty rabbits were randomized into four groups, with 5 rabbits and 60 wounds in each group. Group A was the control group, treated with normal saline daily. Groups B, C, and D were the treatment groups at three different doses of ASMq （400, 800, and 1200 mg/kg body weight, respectively, daily, by gastrogavage）. Twenty wounds were randomly chosen from each group on the 40th day after treatment and specimen were examined. Scar elevation index （SEI） was analyzed with histological assessment, and ultrastructure analysis was analyzed with a transmission electron microscopy. Results： Groups B, C, and D demonstrated significant reductions in SEI as compared with the control group at 35.9% （P=0.0212）, 48.2% （P=0.0108）, and 52.7% （P=0.0103）, respectively in a dose-response manner. SEI was lowered in Group D compared with Group B with a significant difference （P=0.015）. However, there were no significant differences between Groups B and C, or between Groups C and D. Histological analysis showed that high- dose ASMq （1200 mg/kg） could enhance the softening of HTS of rabbit ears and increase the compliance as shown in general. Ultrastructure analysis showed that with increased ASMq dose, the fibroblasts, pro-collagen, collagen, endoplasmic reticulum and ribosomes were reduced gradually. Conclusions： Orally administered ASMq significantly reduces the severity of HTS in the rabbit ear model. The findings of this study may have clinical implications on the management of human HTS.
